|Awarded On||August 21, 2019|
|Title||Therapeutic Targeting of EWS-FLI1 Turnover in Ewing Sarcoma|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||Ralf Kittler|
*Pending contract negotiation
Ewing sarcoma is a cancer that mainly grows in the bones of children and teenagers. If found early, it can be cured with surgery, radiation and chemotherapy, however these treatments have serious side effects in young people, and are often ineffective. We propose to lay the groundwork for a new therapy that has less side effects, and could also be effective when the standard treatment fails. Our proposed strategy may achieve that by developing a drug that decreases the amount of a protein, EWS-FLI1 that is only produced by Ewing sarcoma cells, and essential for these cancer cells to grow and survive. We previously found that ERG, a protein very similar to the FLI1 part of EWS-FLI1, is stabil...